JP2021519783A5 - - Google Patents

Info

Publication number
JP2021519783A5
JP2021519783A5 JP2020552849A JP2020552849A JP2021519783A5 JP 2021519783 A5 JP2021519783 A5 JP 2021519783A5 JP 2020552849 A JP2020552849 A JP 2020552849A JP 2020552849 A JP2020552849 A JP 2020552849A JP 2021519783 A5 JP2021519783 A5 JP 2021519783A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
independently selected
heterocycloalkyl
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020552849A
Other languages
English (en)
Japanese (ja)
Other versions
JP7350005B2 (ja
JP2021519783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024645 external-priority patent/WO2019191470A1/en
Publication of JP2021519783A publication Critical patent/JP2021519783A/ja
Publication of JP2021519783A5 publication Critical patent/JP2021519783A5/ja
Priority to JP2023090963A priority Critical patent/JP2023101762A/ja
Application granted granted Critical
Publication of JP7350005B2 publication Critical patent/JP7350005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020552849A 2018-03-30 2019-03-28 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法 Active JP7350005B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090963A JP2023101762A (ja) 2018-03-30 2023-06-01 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
CNPCT/CN2018/081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090963A Division JP2023101762A (ja) 2018-03-30 2023-06-01 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法

Publications (3)

Publication Number Publication Date
JP2021519783A JP2021519783A (ja) 2021-08-12
JP2021519783A5 true JP2021519783A5 (enExample) 2022-04-05
JP7350005B2 JP7350005B2 (ja) 2023-09-25

Family

ID=67439309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552849A Active JP7350005B2 (ja) 2018-03-30 2019-03-28 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法
JP2023090963A Withdrawn JP2023101762A (ja) 2018-03-30 2023-06-01 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090963A Withdrawn JP2023101762A (ja) 2018-03-30 2023-06-01 Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法

Country Status (21)

Country Link
US (1) US11524960B2 (enExample)
EP (1) EP3774805B1 (enExample)
JP (2) JP7350005B2 (enExample)
KR (1) KR102736073B1 (enExample)
CN (1) CN111936499B (enExample)
AR (1) AR115326A1 (enExample)
AU (1) AU2019243289B2 (enExample)
BR (1) BR112020020104A2 (enExample)
CA (1) CA3094476C (enExample)
EA (1) EA202092320A1 (enExample)
ES (1) ES2973114T3 (enExample)
HU (1) HUE066282T2 (enExample)
IL (1) IL277665B2 (enExample)
MA (1) MA52232A (enExample)
MX (1) MX2020010005A (enExample)
PH (1) PH12020551507A1 (enExample)
PL (1) PL3774805T3 (enExample)
SG (1) SG11202009195WA (enExample)
TW (1) TWI719437B (enExample)
UA (1) UA127059C2 (enExample)
WO (1) WO2019191470A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US12077534B2 (en) * 2018-12-27 2024-09-03 Les Laboratoires Servier Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
AU2019414446A1 (en) * 2018-12-27 2021-07-15 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
AR119046A1 (es) * 2019-05-31 2021-11-17 Agios Pharmaceuticals Inc Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040B1 (en) * 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
TW202214630A (zh) * 2020-09-12 2022-04-16 大陸商成都倍特藥業股份有限公司 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022143864A1 (zh) 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
JP7721686B2 (ja) * 2021-06-02 2025-08-12 南京正大天晴制薬有限公司 メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
CN118742550B (zh) * 2022-03-11 2025-09-05 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
AU2023299635A1 (en) 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
EP4582423A1 (en) 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4729518A1 (en) * 2023-06-14 2026-04-22 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP5993742B2 (ja) 2009-10-29 2016-09-14 ジェノスコ キナーゼ阻害剤
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
UA125852C2 (uk) 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Similar Documents

Publication Publication Date Title
JP2022516883A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2024522766A5 (enExample)
KR102166002B1 (ko) 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
JP2023520333A5 (enExample)
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
JP2023529701A5 (enExample)
CN113316574A (zh) Shp2抑制剂及其应用
KR101671761B1 (ko) 이미다조옥사진 화합물에 의한 항종양 효과 증강제
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CN109069504A (zh) 氨基噻唑化合物及其用途
JP2021501145A5 (enExample)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2020534300A5 (enExample)
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
JP2024516353A5 (enExample)
JP2025540059A (ja) チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の組合せおよびその使用
JP4852605B2 (ja) 放射線治療増強剤
JP2024515061A5 (enExample)
CN110240587A (zh) 一类芳基二氟苄基醚类化合物、制备方法及用途
CA3195465A1 (en) Succinate and crystal form thereof as therapeutics
JP2005531563A5 (enExample)
JP2022521474A5 (enExample)